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ABSTRACT: Bevacizumab is a vascular endothelial growth factor–directed humanized monoclonal antibody used to treat many types of cancer
and some eye diseases. Due to inhibition of angiogenesis, many adverse reactions such as bowel necrosis, nasal septal perforation, and renal
thrombotic microangiopathy have been described. However, its association with interstitial pneumonitis is scarcely reported in the literature. We
report a case of a 79-year-old woman with metastatic colon cancer who presented with cough and dyspnea on exertion the day after initiation
of bevacizumab. She was found to have bilateral airspace opacities on imaging. Infectious and cardiogenic etiologies of dyspnea were ruled
out. Due to the temporal relationship with the initiation of chemotherapy, she was suspected to have developed bevacizumab-induced interstitial
pneumonitis. She improved rapidly with high-dose steroids. Follow-up imaging showed resolution of infiltrates. This is the first reported case in
the literature that directly links bevacizumab to interstitial pneumonitis.
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Introduction

department with dry cough and worsening dyspnea on exertion
of 1-day duration. She was diagnosed with colon cancer in
2015 and underwent left-sided colectomy and then was treated
with adjuvant chemotherapy (5-fluorouracil [5-FU] for a total
of 6 cycles). In 2018, she developed left lower extremity edema
and was diagnosed with deep venous thrombosis of the left
femoral vein and left great saphenous vein and was placed on
rivaroxaban. Extensive workup showed metastatic disease to
the lungs, adrenal glands, and pelvic lymph nodes. Biopsy of
one of the nodes confirmed adenocarcinoma of the colon. She
was started on the combination of capecitabine 1000 mg twice
a day (day 1 to day 14 every 21 days) and bevacizumab 7.5 mg/
kg (day 1 every 21 days) and received the first dose of bevacizumab 1 week after starting capecitabine; she has never been on
those drugs before. Less than 24 hours after the bevacizumab
dose, she started having a dyspnea on exertion that was worsening and was associated with a dry cough and fatigue.
She was tachycardic and tachypneic on admission (heart rate
was 122 bpm, respiratory rate was 24 breaths/min). Her blood
pressure was 163/110 mm Hg. Her Sao2 was 84% on room air.
She was placed on noninvasive positive pressure ventilation for
respiratory distress with minimal improvement on oxygen
delivery therapies. Stat arterial blood gas showed acute hypoxic
respiratory failure (pH of 7.26, Pco2 of 47, Po2 of 248, HCO3 of
21). She was subsequently intubated and required intensive care.
Her admission blood work was significant for mild leukocytosis (white blood cell count of 13.42/μL, with 82% neutrophils) (see Table 1). Chest radiograph showed bilateral
basilar opacities (see Figure 1). Computed tomography (CT)
of the chest with intravenous contrast redemonstrated

Targeting the tumor microenvironment has been adopted by
scientists since decades in the development of new drugs against
cancer. It was found that the growth of tumor cells was strongly
dependent on the formation of new blood vessels called neoangiogenesis, supplementing them with oxygen and nutrients and
aiding in the removal of waste products as well. Upon the different angiogenic activators involved in cancer proliferation, the
family of vascular endothelial growth factor (VEGF) and their
receptors have been one of the most interesting targets for scientists and clinicians.1,2 Bevacizumab, a recombinant humanized monoclonal immunoglobulin-1 (IgG1) antibody directed
against VEGF, has been widely used in the treatment of many
cancers, including colorectal and breast cancers, and its applications has broadened further to treat many eye diseases including
age-related macular degeneration.3,4 It functions as a competitive inhibitor of the tumor-secreted VEGF by preventing its
association with its receptors on neighboring endothelial cells.5
As a result, several adverse reactions have been associated with
the use of this inhibitor, including, but not limited to, hypertension, thromboembolism, proteinuria, and impaired wound
healing.6 Well-established bevacizumab-associated pulmonary
toxicities include hemoptysis and pulmonary hemorrhage.7
Here, we report a rare case of bevacizumab-induced interstitial
pneumonitis in a patient with metastatic colon cancer receiving
capecitabine and bevacizumab.

Case Report

A 79-year-old woman with stage IV colon cancer, metastatic to
the lungs and the adrenal glands, presented to the emergency
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Table 1. Admission laboratory values including hematology and
chemistry.
WBC

13.42

RBC

4.04

Hemoglobin

12.0

Hematocrit

35.1

Mean cell volume

86.9

Platelet

247

Sodium

132

Potassium
Chloride

4.6
101

Carbon dioxide

21

BUN

20

Creatinine
Anion gap
Glucose
Calcium
eGFR

1.1
10
145
9.1
48

Abbreviations: BUN, blood urea nitrogen; eGFR, estimated glomerular filtration
rate; RBC, red blood cell; WBC, white blood cell.

Figure 2. Computed tomography of the chest on admission showing
bilateral ground glass opacities with a slight central distribution.

Figure 1. Chest radiograph on admission showing basilar opacities,
blunting of the costophrenic angles, and reticular markings.

bilateral airspace opacities with a slight central distribution
(see Figure 2).
She was started on broad-spectrum antibiotics due to suspicion of multifocal pneumonia. All cultures and gram stains for
infectious etiologies including common bacteria, fungi,
legionella, viruses, and Pneumocystis were negative. Intravenous
antibiotics were discontinued when cultures came back negative; patient received antibiotics a total of 5 days. Bronchoscopy

and bronchoalveolar lavage (BAL) were performed, and cytological examination of BAL fluid sample showed rare mildly
atypical cells; it favored reactive mesothelial cells, histiocytes,
and bronchial cells in a background of marked acute inflammation. Cultures of BAL were negative for bacteria, mycobacteria,
or fungal pathogens. Pneumocystis jiroveci was not detected by
polymerase chain reaction. Transthoracic echocardiogram
showed a left ventricular ejection fraction of 55%, a grade I
diastolic dysfunction, and moderate pulmonary hypertension.
On day 6 of hospitalization, the patient was started on intravenous methylprednisolone 60 mg given every 8 hours with the
aim to treat presumed interstitial pneumonitis. Subsequently,
the patient’s condition improved significantly, and she was
extubated within 2 days of corticosteroid therapy initiation.
Post-extubation, bilevel positive airway pressure–assisted ventilation was used as needed and she was subsequently transitioned to daily oral prednisone 40 mg. Arterial blood gas
analysis on 3 L nasal cannula then showed a pH of 7.54, Pco2
of 38, Po2 of 159 and an oxygen saturation of 98%. Chest radiograph on discharge showed partial resolution of the bibasilar
opacities (see Figure 3). Eventually, the patient was discharged
after 3 weeks on therapeutic subcutaneous enoxaparin and
long-term oxygen therapy as needed with a gradual taper of

Pervaiz et al

Figure 3. Chest radiograph on the day of discharge showing
improvement of the basilar opacities.

steroid. She eventually signed a Do Not Resuscitate/Do Not
Intubate form and was put on hospice care. No further chemotherapy was administered.

Discussion

The close association of this patient’s acute symptoms with the
administration of the VEGF inhibitor renders this case unique
and interesting. In a case report describing interstitial pneumonitis in a patient treated with the combination of bevacizumab
and pegylated liposomal doxorubicin for metastatic breast cancer, cough and dyspnea started after 3 courses of treatment.8
Another case has reported the diagnosis of acute lung injury in
a patient with metastatic breast cancer to the lung right after
the initiation of the second cycle of bevacizumab and
doxorubicin.9 Finally, acute interstitial pneumonitis (AIP) was
described just after 2 doses of the combination FOLFIRI + bevacizumab in a patient treated for metastatic colon cancer.10
Bevacizumab is widely used and is considered a relatively safe
drug, but nonetheless reports are available regarding rare but
serious lung injuries associated with this drug, including
chronic interstitial pneumonia, alveolar hemorrhage, and
AIP.1,10 The term “acute lung injury” has been used to describe
those entities in a simplified way.
Our patient was only exposed to 1 dose of bevacizumab
and developed a dry cough with worsening shortness of
breath on exertion the next day. In addition, she has been
having capecitabine daily for at least 1 week. No cases of
acute lung injury have been described with the sole use of
fluoropyrimidines such as capecitabine or 5-FU. However,
the entity has been described when the latter was used with
oxaliplatin in the FOLFOX regimen used for the treatment
of colon cancer11 and gastric cancer.12 Another chemotherapeutic agent known to be associated with lung injury is the
nucleoside analog gemcitabine in the treatment of pancreatic
adenocarcinoma13 and the microtubule inhibitor docetaxel in
the treatment of prostate and breast cancer.14 It is not well
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understood how VEGF inhibition can lead to lung toxicities;
however, studies in vitro showed that the protein VEGF can
protect against epithelial apoptosis via a mechanism involving thrombospondin-1, and hence, decrease in its concentration may contribute to the proliferation of fibrosis.15,16 It is
likely in this case that the acute lung injury was the result of
an idiosyncratic reaction to bevacizumab; however, the likelihood that this was caused by a cumulative toxic dose of
capecitabine, which is not even known to cause any lung toxicities, is still possible but highly unlikely. Capecitabine was
implicated in pulmonary toxicity when it was administered
with oxaliplatin in a patient with colorectal cancer,17 the latter being known to cause lung injury. Ruling out an infectious etiology was essential because patients on chemotherapy
are usually immunosuppressed and an opportunistic pneumonia is high on the differential diagnosis in this setting.
Moreover, the resolution of the infiltrates after a course of
corticosteroids supports the diagnosis of pneumonitis over
other etiologies such as multifocal pneumonia or congestive
heart failure exacerbation.
In a retrospective cohort study comparing the incidence of
adverse reactions from the most frequently used monoclonal
antibodies, bevacizumab was the least to cause adverse pulmonary reactions. Advanced age and low serum albumin were significant risk factors for the development of those reactions.
Risk factors associated with pneumonitis during chemotherapy
include older age, low-performance status, and a decreased
normal lung area on CT scan of the chest.10

Conclusion

This patient’s acute respiratory failure may have been caused by
an inflammation in the lung triggered by 1 dose of bevacizumab
giving the pattern of interstitial pneumonitis on CT of the
chest. The ineffectiveness of antibiotics along with the clinical
improvement seen after corticosteroids initiation was in favor of
an inflammatory process causing the symptoms. Although this
is a very rare adverse reaction of bevacizumab, early detection is
essential and crucial for preventing morbidities and mortalities,
as well as unnecessary treatments that might be harmful to
patients who already have a compromised performance status.
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